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Abstract All-cause mortality from cardiovascular disease is
declining in the USA. However, there remains a significant
difference in risk factors for disease and in mortality between
men and women. For example, prevalence and outcomes for
heart failure with preserved ejection fraction differ between
men and women. The reasons for these differences are
multifactorial, but reflect, in part, an incomplete understanding
of sex differences in the etiology of cardiovascular diseases
and a failure to account for sex differences in pre-clinical
studies including those designed to develop new diagnostic
and treatment modalities. This review focuses on the
underlying physiology of these sex differences and provides
evidence that inclusion of female animals in pre-clinical
studies of heart failure and in development of imaging
modalities to assess cardiac function might provide new
information from which one could develop sex-specific
diagnostic criteria and approaches to treatment.
Keywords Diastolic dysfunction . Heart failure with
preserved ejection fraction .Magnetic resonance imaging .
MRI
Introduction
Sex and gender differences are recognized in the incidence,
clinical presentation, and mortality associated with
cardiovascular disease [1, 2]. Unfortunately, sex-specific
diagnostic and treatment modalities have yet to gain similar
attention which, in part, reflect incomplete understanding of
physiological and cellular mechanisms contributing to sex
differences in etiology of some cardiovascular diseases and
failure to consider sex differences in pharmacokinetics and
pharmacodynamics of drugs used to treat most cardiovascular
diseases [3, 4]. Progress in understanding these mechanisms is
slow due to the continued use of male animals in many
types of experiments, lack of reporting of the sex and
hormonal status of animals and cells used in mechanistic
studies, and the absence of reporting of clinical trial results
by sex or gender [5–7].
The incidence of heart failure for persons after the age of
65 years approaches 10 per 1,000 population. Although the
prevalence of heart failure for persons >20 years of age is
greater for males (2.5 %) than females (1.8 %), all age
mortality for women (58.2 %) exceeds that of men (41.8 %)
[2]. Heart failure can be classified as that with reduced
ventricular ejection fraction or with preserved ejection fraction
(HFpEF). The proportion of people with HFpEF has increased
over time and while survival has improved for persons with
reduced ventricular ejection fraction, a similar trend is not
seen with individuals diagnosed with HFpEF. Risk factors
for development of HFpEF include hypertension, renal
insufficiency, and obesity in women, whereas myocardial
ischemia, atrial fibrillation, and chronic obstructive
pulmonary disease are risk factors for development of
HFpEF in men [8, 9]. Adverse outcomes from HFpEF for
men exceed that of women [10, 11]. There are no specific
evidence-based therapies to treat HFpEF [4, 12]. The absence
of such therapies reflects research that has focused on the end-
stage condition and the absence of data linking sex differences
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in causal risk factors to end organ structure and performance.
For example, there is a paucity of data linking underlying
factors contributing to development of hypertension, a risk
factor for HFpEF in women, with investigation of cardiac
remodeling affecting ventricular function in female animals.
Alternatively, studies of cardiac function have ignored the
temporal changes in stimuli (i.e., hypertension) or signaling
pathways leading to the end-stage condition and have not
taken into account sex and hormonal status of the experimental
material [13]. This review will focus on studies investigating
the contribution of sex and sex steroid hormones to
hypertension and cardiac remodeling along with modalities to
assess left ventricular function. Limitations in current research
and recommendations for future areas of study will be
presented.
Etiology of Sex Differences
The fundamental genetic basis of sex differences is the
complement of sex chromosomes: XY for males and XX for
females. About 95 % of the Y chromosome is considered the
male-specific region that does not recombine with the X
chromosome during meiosis. It is inherited directly from
father to sons. Several genes on this chromosome are
associated with several cardiovascular risk factors including
blood pressure, and low-density lipoprotein cholesterol [14,
15]. In men of European lineages, increased risk of
myocardial infarction is also associated with variants on the
male-specific region Y chromosome related to adaptive
immunity [16].
The Y chromosome is required for development of the
testes, the main source of testosterone in men. However,
responsiveness to testosterone requires the androgen receptor
which is located on the X chromosome. Because of mosaic
inactivation of one of the X chromosomes in females,
polymorphisms in genes on portions of the X chromosome
will not be expressed in all tissues as they would be in males.
Thus, X inactivation results in greater variability in
phenotypes in females than males for X-linked traits [17].
The greater variability of physiological responses in females
is used to justify exclusion of female animals frommany basic
science studies. However, expected variability can be
accommodated with appropriate experimental design [18].
The primary source of sex steroid hormones is the testes for
males and the ovaries for females. Sex steroid hormones affect
gene transcription, termed genomic effects, and more rapid
transient effects, termed non-genomic effects. Phenotypic
expression of these effects can be classified as organizational,
i.e., phenotypes which remain after removal of the gonads or
deficiencies in sex hormones, or activational, i.e., phenotypes
which are reversible with removal and replacement of the
specific sex steroid hormone. Thus, sex differences in etiology
of cardiovascular disease will reflect the combined contribution
of the chromosomal complement, and organizational and
activational effects of sex steroid hormones. In females, the
cardiovascular system adapts to the circulatory demands of a
developing fetus. Therefore, underlying mechanisms of
autonomic control of vascular resistance and cardiac function,
volume regulation, and vascular/cardiac remodeling will differ
from males. Accounting for organization and activational
effects of hormones in experimental design requires attention
to hormonal status and pregnancy history.
Sex Differences in Cellular and Molecular Characterization
Linking Hypertension to Cardiac Remodeling
In all ethnic groups, young males tend to have higher mean
systolic and diastolic blood pressures than age-matched
females, and through middle age, the prevalence of
hypertension is higher among males than females. However,
with advancing age, the prevalence of hypertension increases
in females, ultimately surpassing that of age-matched males
[1, 19–23]. Compared to normotensive controls, blood
pressure is proportionally higher in stage 1 hypertensive
premenopausal women than in age-matched men and could
have a greater impact on target organ systems [24]. Nearly
75 % of post-menopausal women in the USA are affected by
some degree of essential hypertension [25, 26]. The
relationship for development of hypertension in women
associated with estrogen deficiency at menopause points to
activational effects of the sex steroids in regulation of blood
pressure.
Since blood pressure is lower in premenopausal compared
to postmenopausal females, hypertension may proportionally
impose a greater hemodynamic load on the heart in young-to-
middle-aged females when compared to age-matched males,
and thus, contribute to greater ventricular remodeling with
hypertension [27–33]. In women, cardiac remodeling in
response to increased volume load associated with pregnancy
is adaptive. However, with aging and development of
hypertension, mechanisms required for cardiac remodeling
in pregnancy could become maladaptive. For example,
women who experience hypertensive disorders of pregnancy
have higher risk for hypertension and other cardiovascular
diseases as they age [34, 35].
Chronic hypertension leading to heart failure involves
persistent activation of the neuron-hormonal axis,
microvascular abnormalities affecting loss of functional
myocytes via apoptosis and fibroblast proliferation, excessive
volume and pressure imposed on remaining viable
myocardium and alterations in the extracellular matrix of the
myocardium, i.e., myocardial remodeling [36–39]. Heart
failure in males also frequently follows myocardial ischemia
or infarctions and mirrors early myocardial remodeling during
the transition from hypertension to heart failure. Most
mechanistic studies linking these processes have not focused
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on sex differences that might affect disease progression. If sex
differences are addressed, the focus is on the contribution of
sex steroid hormones and not on concomitant influence of sex
chromosomal complement. With this in mind; the following
sections will focus on sex differences in components of the
cardiovascular system most likely involved in the progression
of both hypertension and heart failure.
Autonomic Nervous System
Sex differences in autonomic function reflect genetic factors
dictated in part by the Y chromosome. The locus for Sry genes
on the Y chromosome affects development of the testes in
males, but these genes also affect regulation of tyrosine
hydroxylase, an enzyme necessary in the synthesis of
norepinephrine [40, 41]. However, activity of tyrosine
hydroxylase, transport and disposition of norepinephrine are
also affected by the sex steroid hormone, estrogen, in the
periphery and in the brain [42–46]. Consequently, both sex
and hormonal status will affect responses to autonomic
stimulation.
Total peripheral resistance is directly proportional to
sympathetic nerve stimulation in young men [47]. However,
a similar direct relationship is not apparent in young women,
but becomes evident in post-menopausal women and in young
women following blockade of β-adrenergic receptors. These
observations suggest that female sex steroids modulate the
response to sympathetic activation and may involve β-
adrenergic receptors [48, 49].
Other studies also suggest that changes in adrenergic
neurotransmission would provide insight into sex differences
in autonomic regulation of the heart. For example, heart rate
variability decreases in women at menopause [50, 51]. In post-
menopausal women with normal ventricular ejection fraction
and those with systolic dysfunction (heart failure with reduced
ejection fraction), cardiac-specific sympathetic activation and
cardiac norepinephrine spillover was greater than in age-
matched men [52]. Similar comparisons have not been made
between premenopausal women and age-matched men or
between post-menopausal women with and without HFpEF
and age-matched men but perhaps would provide information
to better direct adrenergic related therapies.
Baroreflex sensitivity also is altered by estrogenic
hormones, thus modulating peripheral resistance during the
menstrual cycle, pregnancy, and menopause [53–57].
Although the hormonal shifts of pregnancy modulate
neurotransmission and baroreflex control, hypertension may
precede pregnancy or develop during the course of pregnancy
in the form of pregnancy-induced hypertension, preeclampsia,
or eclampsia [58]. It is unclear at this time whether hormonal
shifts of pregnancy expose an underlying condition or if other
factors associated with defects in the fetal–maternal
circulation precipitate the condition. While one or the other
or both may be causal, hypertensive disorders of pregnancy
increase the life-long risk for development of hypertension
and other cardiovascular pathologies including atrial
fibrillation and heart failure later in life [34, 59]. Specific
associations between hypertensive disorders of pregnancy
and HFpEF remain to be established and the underlying
mechanisms need to be explored in order to develop
appropriate monitoring and risk management strategies to
reduce overall cardiovascular risk for women as they age.
Endothelium and Nitric Oxide
Local control of vascular tone andmicrocirculatory function is
modulated by factors released from the endothelium.
Endothelium-derived nitric oxide is one major contributor to
counteracting sympathetic-mediated vasoconstriction. In
general, loss of nitric oxide is a hallmark of endothelial
dysfunction. In addition to modulating vascular tone, nitric
oxide inhibits cell proliferation and inhibits activation of
platelets and adhesion of monocytes to the endothelium. The
loss of these inhibitory functions contributes to a pro-
coagulatory and pro-inflammatory condition leading to
constriction of coronary arteries and the provocation of
myocardial ischemia and micro-vascular disease (Fig. 1)
[60].
Non-laminar shear stresses resulting from arterial occlusion
further down regulates expression of endothelial nitric oxide
(eNOS) while at the same time increasing release of
inflammatory cytokines and oxidative stress. Together, these
processes would function as a potential positive feedback loop
exacerbating disease processes [61].
Within the myocardium, local synthesis of nitric oxide may
prevent endomyocardial fibrosis by blocking the signaling
cascade involving endothelin, angiotensin II, aldosterone,
and transforming growth factor β [62]. In addition,
excitation–relaxation processes in the myocyte are affected
through nitric oxide mediated increases in cGMP-induced
phosphorylation of troponin. This phosphorylation facilitates
calcium-independent diastolic cross-bridge cycling, post-
translational modifications of titan and, thus, concomitant
myocardium diastolic stiffening [63].
Results of several studies indicate a contribution of cGMP in
regulation of cardiac functioning. In men with coronary heart
disease and systolic dysfunction, 12 months of treatment with
the selective inhibitor of cyclic guanosine monophosphate-
specific phosphodiesterase 5 (PDE-5) increased mean left
ventricular ejection fraction and reduced left ventricular filling
pressures without changes in coronary blood flow [64]. A
multicenter trial is underway to determine if the PDE-5
inhibitor, Sildenafil, would improve exercise capacity and
ventricular remodeling in heart failure with reduced ejection
fraction [65]. Although both men and women are eligible for
this trial, analysis of the resulting data by sex (rather than
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adjusting for sex) will be required to evaluate efficacy of this
therapeutic approach in women with reduced ejection fraction.
Use of phosphodiesterase inhibitors has not proven to be
effective in treatment of HFpEF. Brain-type natriuretic factor
(BNP), which also increases intra-cellular cGMP, is elevated
in heart failure [66, 67]. Based on extensive experimental
evidence derived from animal models of heart failure and
small clinical studies suggesting that increases in cGMPmight
improve cardiac function, a multicenter trial (RELAX) was
initiated to investigate effects of Sildenafil in patients with
HFpEF [68]. However, results of this trial were disappointing
in that there were no improvements in clinical status, exercise
capacity, or ventricular remodeling in the treated group [69].
Although the trial consisted of about 50 % men and women
(most of whom were likely post-menopausal based on age),
the results were not analyzed by sex and many had
confounding conditions such as diabetes which might not
have been modeled in pre-clinical mechanistic studies most
of which were conducted in male animals. Although BNP
levels vary by sex and decade of life [70], no studies have
related levels of BNP to cardiac performance in female
animals taking into account hormonal status.
Adrenergic activation is also blunted by increases in cGMP
[71, 72]. Effects of nitric oxide-like compounds including
PDE-5 inhibitors, also could affect myocardial function
indirectly through interactions with the sympathetic nervous
system. These interactions have not been completely explored
in mechanistic studies using male and female experimental
material. Given the results of trials targeting PDE-5, there is a
need for integrative studies of mechanisms involving NO and
BNP that might differ between males and females of varying
hormonal status to gain new insights into alternative
therapeutic approaches [73].
Production of nitric oxide is modulated by sex steroid
hormones [74]. In general, estrogen upregulates eNOS and
increases bioavailability of nitric oxide [74]. However, in
postmenopausal women with hypertension, effects of
hormonal treatments on synthesis and bioavailability of nitric
oxide may be confounded by other changes in regulatory
systems that are refractory to reversible, activational effects
of hormones [75–77] (Fig. 1). Effects of androgen stimulation
on the NO/eNOS system are controversial [74] in part, due to
the aromatization of testosterone to estrogen.
Metabolism of testosterone by aromatase within the
myocardium can affect cardiac function. Although androgens
have an anabolic effect on cardiac myocytes, estrogen will
reduce calcium sensitivity and subsequently have a negative
inotropic effect on cardiac function [78]. Polymorphisms in
aromatase are associated with sex-specific outcomes for acute
coronary syndrome. In men the CYP19A1 SNP −81371 C>T
associated with increased mortality; the opposite was found
for women. In men with hypertension and coronary artery
disease, this same SNP was associated with increased
mortality, myocardial infarction, and stroke, again, the
opposite was found for women carrying this genetic
polymorphism [79]. Deficiencies in testosterone and other
anabolic steroids are independent negative prognostic
indicators of outcomes for men with systolic heart failure
[80]. Contributions of changes in ratio of bioavailable
androgens including testosterone to estrogen in development
of hypertension and HFpEF in men and menopausal women
need to be explored in more depth as clinical use of
androgenic hormone treatments for men is increasing and their
use in women remains controversial. Specific studies are
needed to consider testosterone concentrations (free vs total)
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Fig. 1 Schematic of relationship
between endothelial cells and nitric
oxide (NO) synthesis, as
implicated in HFpEF
pathophysiology. Pathways shown
represent experimental evidence to
date; avenues for future
experimental investigation are
indicated by question mark.
Abbreviations: NO , nitric oxide;
eNOS, NOS, nitric oxide synthase,
eNOS, endothelial-derived nitric
oxide synthase; nNOS , neuronal
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blood pressure, and other metabolic cardiovascular risk
factors in both men and women.
Renin–Angiotensin–Aldosterone System (RAAS)
Chronic increases in blood pressure and blood volume
activate RAAS. Activation of the RAAS is also associated
with increased levels of TFG-β, in conjunction with the
recruitment of smooth muscle cells, monocytes, and
fibroblasts [81], stimulating a “genetic program of wound
repair” [82]. This genetic program leads to increased
deposition and decreased turnover of extracellular matrix in
the heart and blood vessels and largely mirrors many of the
profibrotic mechanisms detailed later. Ultimately, the parallel
and convergence of RAAS activation and a profibrotic genetic
program results in perivascular scarring and the amplification
of organ damage resulting from hypertensive disease. In
addition, as increased mechanical stretch is a stimulus for
myocyte hypertrophy, with chronic RAAS activation,
sustained increases in blood volume would provide such a
stimulus for cardiomyocyte hypertrophy.
Sex differences in the RAAS have been reviewed recently
[83]. In brief, estrogen upregulates angiotensinogen and it
downregulates renin synthesis, activity of angiotensin-
converting enzyme (ACE) and angiotensin 1 receptor
signaling [84, 85]. Despite beingmechanistically characterized
in vitro by well-defined experimental conditions, clinically
relevant effects of estrogen on RAAS remain inconclusive
[86–88]. Although angiotensin-converting enzyme inhibitors
reduce blood pressure in women, they may cause some side
effects such as coughing and may not reduce blood pressure to
target goals in women as in men [3]. However, in the
I-PRESERVE study of elderly patients with HFpEF, the
angiotensin ll receptor blocker Irbesartan reduced all cause
mortality and heart failure hospitalization more in women than
men [8].
Testosterone also contributes to activation of the RAAS.
Basal ACE activity in the hypertensive rat (mRen(2) Lewis
rat) is higher in males than females [89]. Castration of
male rats reduced ACE activity, whereas testosterone
treatment to ovariectomized female rats increased ACE
activity [90] supporting a sex-independent, but reversible
hormonal activational effect on the enzyme. Sexual
dimorphisms in pro-renin levels have been observed in
humans, with males having significantly higher levels of
renin compared to women [91]. In a study of South
African men and women, testosterone levels in both
hypertensive males and females were significantly higher
compared to normotensive study participants. Collectively,
testosterone may increase the progression of hypertension
to cardiac hypertrophy and subsequent heart failure through
increased angiotensinogen and renin synthesis. Clinical
benefit from angiotensin-converting enzyme inhibitors
may be less in patients with HFpEF than in those with
reduced ejection fraction [92, 93]. Further studies are
required to determine how both testosterone and estrogens
regulate expression of angiotensin receptors, their bio-
distribution with RAAS activation and inactivation of the
RAAS with medications targeting angiotensin-converting
enzymes in women in HFpEF and the relationship to
chronic renal disease [73, 94–99].
Mineralocorticoids are activated during volume expansion.
Aldosterone also affects development of arrhythmias, matrix
deposition, and may also affect glycemic control [12]. As
atrial fibrillation, obesity, and diabetes are also risk factors
for HFpEF, mineralocorticoid receptor antagonists may be
useful in treatment of HFpEF [100, 101]. However, additional
studies are needed to evaluate sex-specific efficacy and effects
of sex steroids on treatment outcomes.
Extracellular Matrix
Ventricular fibrosis characterized by fibroblast proliferation
and deposition of the extracellular matrix ultimately leads to
distortion of cardiac architecture and function. In the heart,
fibrosis can result in ventricular stiffening with impairment of
mechano-electric functions, ion-channel exchange, and cell
signaling, leading to microvascular rarefation and subsequent
diastolic dysfunction. Clinically, an impaired mechanoelectric
coupling increases the risk of arrhythmia-associated
cardiopathies, and marked atrial fibrosis associates with
chronic heart disease [102–105].
Traditionally, it was thought that activated fibroblasts
derive principally from resident fibroblast or from
mesenchymal cells. However, profibrotic cells may derive
from endothelial cells transformed to mesenchymal cells
(EndoMT) [106]. These EndoMT in conjunction with the
active recruitment of profibrotic cells to sites of activation
exacerbate microvascular rarefication [107]. However, little
is known regarding sex differences in differentiation of these
types of cells.
Sex hormones affect cellular differentiation. 17β-Estradiol
limits cardiac fibroblast proliferation and differentiation and
also suppresses DNA synthesis in neonatal cardiac fibroblasts
[102, 105]. Effects of testosterone on development of cardiac
fibrosis are conflicting. Castration, in one study,
significantly increased cardiomyocyte apoptosis and
fibrosis suggesting that the removal of testosterone was
deleterious to cardiac health [108]. Yet other studies
suggest that androgens exacerbate cardiac fibrosis during
aging [109], and excessive testosterone levels increase
myocardial hypertrophy [110], structural alterations, and
induce apoptosis. These discrepancies most likely reflect
difference in experimental material (sex and hormonal
status), genetic or chemically induced heart failure, or
in vivo vs in vitro observations. Careful studies are
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needed that control for sex, hormonal status, and perhaps
aromatase polymorphisms (see above) in order to resolve
these discrepancies.
Sex steroid hormones modulate several enzymes and
growth factors associated with EndoMT [111] and tissue
remodeling including matrix metalloproteinases, transforming
growth factorβ (TGF-β), angiotensin II (AngII), endothelin-1
(ET1), TNF-α, fibronectin, and collagen. Progesterone and
17β-estradiol, alike, increase mRNA of TGF-β and
fibronectin. Conversely, 17β-estradiol mitigates the activation
of AngII and ET1 stimulation, suppressing RAAS activation
while reducing synthesis of mesenchymal proteins
fibronectin, vimentin, and collagens I and III. Taken together,
these observations support that estrogen, most likely through
estrogen receptor-β signaling, retards the development of
cardiac fibrosis and hypertrophy—both of cardiomyocytes,
and on a larger scale, structure, and thus function of the heart
[112, 113]. Serum monitoring of matrix metalloproteinase 9
(MMP9) and tissue inhibitor of metalloproteinase 1 (TIMP1)
may serve as potential biomarkers to assess risk for
development of HFpEF. In a crossover study, the ratio of
MMP9/TIMP1 correlated with the degree of diastolic
dysfunction using a logistic regression model adjusted for
age, sex, systolic blood pressure, and creatinine [114].
Although this study consisted of about 50 %men and women,
data were not dichotomized by sex to determine if there were
sex-specific ranges and it is unclear how these enzymes might
be regulated or elevated in women with a history of
hypertensive pregnancy disorders. Such information is needed
if therapies targeting these enzymatic pathways are to be
developed.
Modalities to Assess Sex Differences in Cardiac Function
Despite macroscopic anatomic similarities in hearts of males
and females, there are sex differences in microarchitecture
which affect cardiac function in response to increasing age
and hormonal status and hypertension. Computed
tomography, magnetic resonance imaging (MRI), and
echocardiography are used in clinical assessment of left
ventricular size, function, and mass to describe cardiac
anatomy and function for diagnosis of cardiovascular
diseases. However, few studies have defined sex-specific
reference values for left ventricular function using these
imaging modalities.
Using echocardiography, left ventricular mass did not
increase with age in men but did so in women even when
indexed to body surface area (Fig. 2) [115–119]. In the
Framingham study, after the age of 60, the prevalence of
left ventricular hypertrophy in females increased by 69 %
per decade of life compared to 15 % in males [120]. The
disparity in left ventricular remodeling is particularly
marked in pressure overload states such as hypertension
[33]. For example, sex differences have been identified
using 2-D and M-mode echocardiographic techniques in
cardiac structure and function with hypertension and its
treatments [121, 122]. The left ventricle of hypertensive
females showed greater fractional shortening, smaller end
diastolic chamber size, and higher ejection fraction than
males. An eccentric pattern of remodeling was more
common in males while a concentric pattern of remodeling
was common in females [123, 124]. With long-term
antihypertensive treatment, hypertensive women retained
higher left ventricular ejection fraction, and stress-
corrected mid-wall shortening in spite of less hypertrophy
regression compared to men [121]. These results suggest
sex differences in cardiac structure and function with
hypertension resulting from the mechanisms discussed in
the previous sections.
3D echocardiography combined with 3D color Doppler
provides improved accuracy and reproducibility over 2D
methods for left ventricular volume and function calculations
and is an efficient tool for assessing systolic and diastolic
dysfunction for diagnosing heart failure [125]. An estimate
of the chamber stiffness can be obtained indirectly using the
pressure–volume relationships where the stiffness is the slope
of the tangent drawn to the curve [126–128]. However, direct
imaging of elastic properties of the heart would move this field
forward and allow for better identification of sex-specific
changes in myocardial stiffness.
Fig. 2 Left ventricular mass determined by echocardiography
normalized to height in healthy men (a) and women (b) by decade of
life. Dashed lines are mean values; solid lines are 95 % confidence
intervals. Left ventricular mass did not increase with age in men
(p =0.73) but did so in women (p =0.03). Reprinted with permission from
Fig. 2 of reference [141]
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Intrinsic mechanical properties of tissues (i.e., stiffness) can
be obtained by applying a mechanical excitation or stress to
tissues and measuring the resulting tissue deformation in
response to that stress based on stress–strain relationships or
models of shear wave propagation. One suchmethod, acoustic
radiation force imaging (ARFI), measures tissue responses by
using radiation force from long pulses to impart localized
displacement of the propagating shear waves. Application of
this technique throughout the cardiac cycle may be useful in
providing insight into sex differences in myocardial
performance [129]. Another technique, shear wave imaging
(SWI) includes imaging the shear wave propagation at an
ultrahigh frame rate (12,000 images/s) using the same
diagnostic probe connected to an ultrafast ultrasonic device
[130].
Cardiac magnetic resonance elastography (CMRE) is a
noninvasive MRI-based phase contrast technique for
quantitative assessment of myocardial stiffness where
propagating shear waves are imaged and tissue stiffness is
derived [131]. A fully functional CMRE demands fast 3D
imaging sequences and robust 3D inversion algorithms for
obtaining stiffness maps from the 3D displacements obtained
from the propagating shear waves. Using this technique,
differences in stiffness were reported in one of five pigs (four
males and one female) in response to an epinephrine challenge
(Fig. 3). However, it is unknown if differences were observed
in the female compared to the male pigs. Given the weight of
the animals, it is unlikely that the pigs had reached sexual
maturity and it is unknown if the males had been castrated at
birth. Such information regarding sex and hormonal status is
critical in order to assess influence of sex from changes in
hormonal status with aging.
Modalities to image elasticity face serious technical
challenges due to the complex 3D geometry and anisotropy
Fig. 3 An example of using
magnetic resonance elastography to
estimate myocardial contractility in
a sexually immature pig. a–d
represent the end-systolic short axis
image of the left ventricle; f–i
represent the end-systolic short axis
after infusion of epinephrine. The
green and orange contours
delineate the myocardium. e
(baseline) and j (after infusion) are
maps of stiffness. Reproduced
with permission from Fig. 3 of
reference [142]
Fig. 4 Diagram depicting where
future research is needed to
include sex and hormonal status
into integrative physiologic
studies of HFpEF. Abbreviation:
RAAS—renin angiotensin/
aldosterone system
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of the heart. However, upon successful resolution of these
challenges, data on sex-specific changes in myocardial
elasticity will open new avenues for differentiating effects of
chromosomal sex from activational and organizational effects
of the sex steroids on cardiac stiffness. Such information is
critical in order to develop sex-specific criteria for diagnosis
and prognosis for treatments of HFpEF.
Moving Forward
Attention of the scientific community has been directed toward
the inability to reproducemany basic science experiments and to
translate their results to the clinical arena [132]. Potential
solutions have been proposed, most of which have focused on
experimental design and statistical analysis (go.nature.com/
oloeip). Some of the difficulty with reproducing experimental
results across laboratories derives from the lack of reporting the
sex of experimental material [6, 133]. In addition, in order to
understand mechanistic pathways of physiological processes,
the sex of the cells/animals must be identified and some
information is needed regarding the hormonal status of the
donor material to control for organizational effects of sex steroid
hormones [134]. Studies of genetic variants (knock-in and
knock-out) in animals must include both males and females as
gene expression in most tissues varies by sex [135–137]. Much
is to be learned regarding why one sex may exhibit a phenotype
while the other may be protected. However, analyzing the data
from mixed groups of males and females may mask an effect
especially if the particular response may be upregulated in one
sex and downregulated in the other. Funding agencies should be
more diligent in requiring appropriate scientific justification for
studying only male animals beyond avoiding increased
variability of data or hormonal variations that are characteristics
of adult females [138]. Experimental design to account for
hormonal variations can be developed. Although including
female animals into the experimental design may increase initial
costs, this investment will be balanced by the cost and time
wasted by developing a therapeutic approach based on one sex
that fails clinical testing due to adverse events in a mixed study
population of men and women [139, 140].
Conclusion
Sex differences in the regulation of the cardiovascular system
reflect the influence of the sex chromosomes and sex steroid
hormones. Sex-specific risks for development of hypertension
and type and severity of heart failure reflect the interactions of
these influences. Shifts in circulating concentrations of sex
steroids that accompany pregnancy and menopause in women
affect autonomic and endothelial regulation of vascular tone,
vasoactive cytokines, and hormones of the rennin–
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changes will affect the risk, onset, and severity of
hypertension and functional and structural characteristics of
the heart leading to heart failure (Table 1). In order to improve
diagnosis and treatment for men and women with heart
failure, mechanistic studies of cellular contributions to
cardiovascular control need to be explored in female animals
and in women of known hormonal status. In addition, imaging
modalities must be developed to detect changes in elasticity
and performance of the heart both as a tool to understand
mechanistic integration of cardiac function and for diagnostic
and prognostic purposes. Understanding of myocardial
remodeling affecting function continues to evolve. Focusing
attention on sex differences in development of chronic
diseases may result in sex-specific diagnostic and
treatment modalities which could improve outcomes
and reduce disparities in sex differences in mortality from
these diseases.
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